南方科技大学知识苑(SUSTech KC): Evolving immune evasion and transmissibility of SARS-CoV-2: The emergence of JN.1 variant and its global impact

题名	Evolving immune evasion and transmissibility of SARS-CoV-2: The emergence of JN.1 variant and its global impact
作者	Ou, Guanyong1,2 ; Yang, Yang 1,2 ; Zhang, Shengjie1,2 ; Niu, Shiyu1,2 ; Cai, Qingxian 1,2; Liu, Yingxia 1,2,3; Lu, Hongzhou 1,2,3
通讯作者	Liu, Yingxia; Lu, Hongzhou
发表日期	2024-02-01
DOI	10.5582/ddt.2024.01008
发表期刊	DRUG DISCOVERIES AND THERAPEUTICS 影响因子和分区
ISSN	1881-7831
EISSN	1881-784X
卷号	18 期号:1
摘要	The continuous evolution of SARS-CoV-2 variants constitutes a significant impediment to the public health. The World Health Organization (WHO) has designated the SARS-CoV-2 variant JN.1, which has evolved from its progenitor BA.2.86, as a Variant of Interest (VOI) in light of its enhanced immune evasion and transmissibility. The proliferating dissemination of JN.1 globally accentuates its competitive superiority and the potential to instigate fresh surges of infection, notably among cohorts previously infected by antecedent variants. Notably, prevailing evidence does not corroborate an increase in pathogenicity associated with JN.1, and antiviral agents retain their antiviral activity against both BA.2.86 and JN.1. The sustained effectiveness of antiviral agents offers a beacon of hope. Nonetheless, the variant's adeptness at eluding the immunoprotective effects conferred by extant vaccines highlights the imperative for the development of more effective vaccines and therapeutic approaches. Overall, the distinct evolutionary trajectories of BA.2.86 and JN.1 underscore the necessity for ongoing surveillance and scholarly inquiry to elucidate their implications for the pandemic's evolution, which requires the international communities to foster collaboration through the sharing of data, exchange of insights, and collective scientific endeavors.
关键词	SARS-CoV-2 variants JN.1 immune evasion vaccine refinement global public health
相关链接	[来源记录]
收录类别	ESCI
语种	英语
学校署名	第一 ; 通讯
资助项目	Shenzhen Science and Technology Program["JSGG 2 0 2 2 0 2 2 6 0 9 0 2 0 3 0 0 6","JSGG20220226085800001"]
WOS研究方向	Pharmacology & Pharmacy
WOS类目	Pharmacology & Pharmacy
WOS记录号	WOS:001170192100001
出版者	INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENT
来源库	Web of Science
引用统计	被引频次[WOS]：3
成果类型	期刊论文
条目标识符	http://sustech.caswiz.com/handle/2SGJ60CL/789074
专题	南方科技大学第二附属医院南方科技大学第一附属医院
作者单位	1.Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Shenzhen Key Lab Pathogen & Immun, Shenzhen Clin Res Ctr Infect Dis,Hosp 2,State Key, Shenzhen, Guangdong, Peoples R China 2.Natl Clin Res Ctr Infect Dis, Shenzhen, Guangdong, Peoples R China 3.Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Shenzhen Key Lab Pathogen & Immun, Shenzhen Clin Res Ctr Infect Dis,Hosp 2,State Key, Shenzhen, Peoples R China
第一作者单位	南方科技大学第二附属医院; 南方科技大学第一附属医院
通讯作者单位	南方科技大学第二附属医院; 南方科技大学第一附属医院
第一作者的第一单位	南方科技大学第二附属医院; 南方科技大学第一附属医院
推荐引用方式 GB/T 7714	Ou, Guanyong,Yang, Yang,Zhang, Shengjie,et al. Evolving immune evasion and transmissibility of SARS-CoV-2: The emergence of JN.1 variant and its global impact[J]. DRUG DISCOVERIES AND THERAPEUTICS,2024,18(1).
APA	Ou, Guanyong.,Yang, Yang.,Zhang, Shengjie.,Niu, Shiyu.,Cai, Qingxian.,...&Lu, Hongzhou.(2024).Evolving immune evasion and transmissibility of SARS-CoV-2: The emergence of JN.1 variant and its global impact.DRUG DISCOVERIES AND THERAPEUTICS,18(1).
MLA	Ou, Guanyong,et al."Evolving immune evasion and transmissibility of SARS-CoV-2: The emergence of JN.1 variant and its global impact".DRUG DISCOVERIES AND THERAPEUTICS 18.1(2024).